PCI Biotech Holding ASA announced that the European Patent Office (EPO) has informed PCI Biotech that they intend to grant a new patent covering delivery of mRNA by use of PCI Biotech?s fimaNAc technology. This application is primarily foreseen to be used for dermatology. Nucleic acid therapeutics, including mRNAs, have the potential to improve the treatment of dermatological diseases, but delivery to skin lesions remains an obstacle. This is a challenge PCI Biotech?s fimaNAc technology is uniquely positioned to solve, by light-directed intracellular nucleic acid delivery. The European patent secures protection until 2039 and this patent application is pending in the US and key Asian
markets.